CA2212370A1 - Inhibition of angiogenesis using interleukin-12 - Google Patents

Inhibition of angiogenesis using interleukin-12

Info

Publication number
CA2212370A1
CA2212370A1 CA002212370A CA2212370A CA2212370A1 CA 2212370 A1 CA2212370 A1 CA 2212370A1 CA 002212370 A CA002212370 A CA 002212370A CA 2212370 A CA2212370 A CA 2212370A CA 2212370 A1 CA2212370 A1 CA 2212370A1
Authority
CA
Canada
Prior art keywords
angiogenesis
treatment
interleukin
mice
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002212370A
Other languages
English (en)
French (fr)
Inventor
Moses Judah Folkman
Gary Arthur Truitt
Emile Eugene Voest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Childrens Medical Center Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2212370A1 publication Critical patent/CA2212370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002212370A 1995-02-16 1996-02-07 Inhibition of angiogenesis using interleukin-12 Abandoned CA2212370A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38938295A 1995-02-16 1995-02-16
US08/389,382 1995-02-16

Publications (1)

Publication Number Publication Date
CA2212370A1 true CA2212370A1 (en) 1996-08-22

Family

ID=23538033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002212370A Abandoned CA2212370A1 (en) 1995-02-16 1996-02-07 Inhibition of angiogenesis using interleukin-12

Country Status (8)

Country Link
EP (1) EP0809511A1 (xx)
JP (1) JPH11500119A (xx)
AU (1) AU4788396A (xx)
BR (1) BR9607427A (xx)
CA (1) CA2212370A1 (xx)
FI (1) FI973356A (xx)
TR (1) TR199700801T1 (xx)
WO (1) WO1996025171A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243161A1 (en) * 1996-11-22 1998-05-28 Toray Industries, Inc. Use of interferon-beta to treat retinal edema
US5981508A (en) 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
EP0986393B1 (en) * 1997-05-27 2004-03-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
CA2308438A1 (en) * 1997-11-03 1999-05-14 The Wistar Institute Of Anatomy And Biology Method and compositions for inhibiting angiogenesis and treating cancer
WO2002079157A1 (en) 2001-03-29 2002-10-10 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
KR20190039145A (ko) * 2016-07-18 2019-04-10 뉴메디슨즈, 인코포레이티드 대체 면역요법으로서의 il-12의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013794A1 (en) * 1992-01-16 1993-07-22 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法

Also Published As

Publication number Publication date
JPH11500119A (ja) 1999-01-06
MX9706188A (es) 1997-11-29
TR199700801T1 (xx) 1998-03-21
EP0809511A1 (en) 1997-12-03
AU4788396A (en) 1996-09-04
FI973356A0 (fi) 1997-08-15
FI973356A (fi) 1997-08-15
WO1996025171A1 (en) 1996-08-22
BR9607427A (pt) 1998-06-23

Similar Documents

Publication Publication Date Title
EP0688211B1 (en) Thalidomide for inhibition of angiogenesis
USRE40360E1 (en) Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide
US6228879B1 (en) Methods and compositions for inhibition of angiogenesis
US20020161023A1 (en) Method of treating diseases using 3-amino thalidomide
CA2212370A1 (en) Inhibition of angiogenesis using interleukin-12
US20120142734A1 (en) Methods for treating tumors with thalidomide
US6890906B2 (en) Method for controlling angiogenesis in animals
MXPA97006188A (en) Inhibition of angiogenesis using interleucin
US20020098176A1 (en) Inhibition of tumor growth by a nematode anticoagulant protein
CN1189102A (zh) 白细胞介素－12对血管生成的抑制作用

Legal Events

Date Code Title Description
FZDE Dead